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Targeted next-generation 
sequencing as a comprehensive  
test for Mendelian diseases: a 
cohort diagnostic study
Yan Sun1,2,3, Jianfen Man3, Yang Wan4, Gao Pan3, Lique Du3, Long Li3, Yun Yang3, Liru Qiu5, 
Qing Gao6, Handong Dan6, Liangwei Mao3, Zhengyu Cheng3, Chen Fan3, Jing Yu2,7, 
Mufei Lin2,7, Karsten Kristiansen  1, Yin Shen6 & Xiaoming Wei3
With the development of next generation sequencing, more and more common inherited diseases 
have been reported. However, accurate and convenient molecular diagnosis cannot be achieved easily 
because of the enormous size of disease causing mutations. In this study, we introduced a new single-
step method for the genetic analysis of patients and carriers in real clinical settings. All kinds of disease 
causing mutations can be detected at the same time in patients with Mendelian diseases or carriers. 
First, we evaluated this technology using YH cell line DNA and 9 samples with known mutations. 
Accuracy and stability of 99.80% and 99.58% were achieved respectively. Then, a total of 303 patients 
were tested using our targeted NGS approaches, 50.17% of which were found to have deleterious 
mutations and molecular confirmation of the clinical diagnosis. We identified 219 disease causing 
mutations, 43.84% (96/219) of which has never been reported before. Additionally, we developed a 
new deleteriousness prediction method for nonsynonymous SNVs, and an automating annotation and 
diagnosis system for Mendelian diseases, thus greatly assisting and enhancing Mendelian diseases 
diagnosis and helping to make a precise diagnosis for patients with Mendelian diseases.
Mendelian diseases are a series of diseases following the principles of Mendelian inheritance. So far, more than 
8,000 Mendelian inheritance diseases have been included in Online Mendelian Inheritance in Man (the OMIM 
database, www.omim.org). Many methods have been performed for the diagnosis of Mendelian diseases in clin-
ical practice, for example, Sanger sequencing of known disease causing genes. As is known, Sanger sequencing 
is widely considered as the gold standard for sequencing, however, there are some drawbacks in this technology: 
laborious, expensive, and time consuming.
With the rapid development of next generation sequencing (NGS) technology, all kinds of diseasing causing 
mutations, such as SNVs (single nucleotide variants), Indel (small insertion/deletion) and CNVs (copy number 
variants), can be detected at the same time in patients with Mendelian diseases or carriers1. It has been proved 
that NGS based technology is a powerful tool for the detection of pathogenic mutations, especially in patients 
with monogenic disorders2. Researchers performed NGS to analyze tens to thousands of genes simultaneously 
in a single assay1,3,4. This makes NGS more suitable in the diagnosis of Mendelian diseases, and highly improved 
the diagnostic yield5. Comprehensive characterization of genetic diseases using NGS technology has become 
an option for researchers and clinicians. However, annotation and interpretation of NGS data is tedious and 
time-consuming, and require highly specific expertise in this filed. Our new method introduced here can help 
clinical scientists to efficiently integrate all their data more quickly and form a whole picture of the detected 
variants.
1Department of Biology, University of Copenhagen, Copenhagen, DK-2200, Denmark. 2BGI Genomics, BGI-
Shenzhen, Shenzhen, 518083, China. 3BGI-Wuhan, BGI-Shenzhen, Wuhan, 430074, China. 4Fuyang People’s Hospital, 
Fuyang, 236000, China. 5The Nephrology Division of Department of Pediatrics, Tongji Hospital, Tongji Medical 
College, Huazhong University of Science and Technology, Wuhan, 430030, China. 6Eye Center, Renmin Hospital of 
Wuhan University, Wuhan University, Wuhan, 430060, China. 7China National GeneBank, BGI-Shenzhen, Shenzhen, 
518120, China. Yan Sun, Jianfen Man and Yang Wan contributed equally to this work. Correspondence and requests 
for materials should be addressed to Y.S. (email: yinshen@whu.edu.cn) or X.W. (email: weixm@genomics.cn)
Received: 12 March 2018
Accepted: 23 July 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIFIC REPoRTS |  (2018) 8:11646  | DOI:10.1038/s41598-018-30151-z
WGS (whole genome sequencing) and WES (Whole exome sequencing) have been applied in the diagnostic 
of Mendelian genetic disorders or the screening of carriers6–9. However, it is still a major challenge to detect few 
disease causing mutations in the vast potential variants in human genome10. Targeted NGS is recognized as a 
cost effective method for the diagnostic of Mendelian genetic disorders1,3,4. Targeted NGS with high throughput 
and lower cost can target disease related regions in human genome more efficiently, and detect variants more 
sensitively. This technology has been widely used in the screening of mutations and effective diagnosis of genetic 
diseases in clinical setting11–14. What is more, targeted NGS targets a set of genes related to specific disease pheno-
types, which could result in a higher sequencing coverage. Variant calling is more accurate for region of interest 
when performing targeted NGS15.
In this study, we designed a chip (array based) containing 4,689 nuclear genes related to Mendelian diseases, 
and tested its performance in detecting clinical relevant mutations using HiSeq platform. Then, we applied this 
panel to 303 clinical cases, and identified disease causing mutations in 152 patients. What is more, we developed a 
new deleteriousness prediction method for nonsynonymous SNVs, and an automating annotation and diagnosis 
system for Mendelian diseases. It can greatly assist and enhance Mendelian diseases diagnosis and help to make 
a precise diagnosis for the patients.
Results
Evaluation of accuracy and stability. Before applying this technology to real clinical patients, we eval-
uated the accuracy and stability of targeted NGS as reported before1. To assess the accuracy of this technology, 
we compared the SNPs of a YH cell line sample (C1) detected using targeted NGS with the genotyping results 
detected using Illumina’s Human Zhonghua-8 Bead Chips (SNP Array). The analysis of C1 using SNP Array was 
carried out blindly. In C1, there are a total of 4416 SNPs detected in the region of the chip (10,258,198 bp). In 
the selected loci, 99.80% (4,407/4,416) genotypes detected by targeted NGS in sample C1 were accordant to the 
results detected by SNP Array, which showed a high accuracy of our method. We also screened the 4,689 nuclear 
genes in 9 probands with known mutations using targeted NGS to evaluate the technology (Table 1). Sanger 
sequencing and real-time PCR validation of the known mutations in the 9 probands had been completed prior 
to this study. A total of 11 known mutations were detected in the 9 probands using targeted NGS technology. 
The results are exactly the same as obtained using real-time PCR and Sanger sequencing, indicating complete 
consistency of the methods. These results indicated that targeted NGS technology used in this study provides 
high accuracy.
To assess the stability of the technology, YH cell line were sequenced three times in different batches (C1, C2 
and C3). There are 10,133,027 genotype can be detected in the 3 YH cell line samples. We then compared all the 
genotypes detected in C1, C2 and C3. The results showed that the proportion of the same genotype detected is 
99.58% (10,090,060/10,133,027) in different batches, which indicated high stability of this technology.
Targeted NGS approach. In this study, we developed a targeted NGS assay to detect disease causing alter-
ations in 303 patients diagnosed with Mendelian diseases using HiSeq platform.
A total of 303 patients were recruited in this study. Using targeted NGS, we obtained high-quality reads of all 
the samples. After base calling and image analysis using Illumina HiSeq sequencers, primary data was received 
in the form of FASTQ. Then we performed a new bioinformatics analysis pipeline to analyze the raw sequencing 
data. The sequencing results of all the patients are as follows: more than 99.55% coverage of the target region was 
achieved for each sample, and an average sequencing depth of 250.82-fold was achieved for each sample.
Deleteriousness prediction for nonsynonymous SNVs. In order to attain the best classifier for rare 
missense variants in human genome, we developed a new pathogenicity prediction method (MPPS, Mutation 
Pathogenicity Prediction Software) in this study. MPPS combined a total of 17 current deleteriousness-scoring 
methods, including 8 functional prediction scores (Polyphen2_HDIV16, Polyphen2_HVAR16, MutationTaster17, 
SIFT18, LRT19, FATHMM20, MutationAssessor21 and M-CAP22), 7 new prediction scores (PROVEAN23, VEST324, 
MetaSVM25, MetaLR25, fathmm-MKL26, CADD27 and DANN28) and 2 conservation scores (GERP++29 and 
phyloP100way30).
In the present study, we evaluated the performance of the 17 deleteriousness prediction methods and MPPS 
(Fig. 1). We collected a total of 25,220 known pathogenic variants from ClinVar (www.ncbi.nlm.nih.gov/clinvar), 
Proband Disease Gene Mutation Validation
P1 Dent Disease 1 CLCN5 c.778_798delACTCTGGTTATCAAAACCATC Sanger
P2 X-Linked Ichthyosis STS Whole gene deletion QPCR
P3 Mucolipidosis II/III Alpha&Beta GNPTAB c.1090 C > T; c.2404 C > T Sanger
P4 Charcot-Marie-Tooth disease PMP22 c.215 C > T Sanger
P5 Polycystic kidney disease 1 PKD1 c.8835 C > G Sanger
P6 Duchenne/Becker Muscular Dystrophy DMD CDS 10–12 deletion QPCR
P7 Nephrotic Syndrome Type 2 NPHS2 c.593 A > C; c.538 G > A Sanger
P8 Pseudohypoaldosteronism Type IB SCNN1B c.1853C > G Sanger
P9 Charcot-Marie-Tooth disease PMP22 Whole gene duplication QPCR
Table 1. Nine probands with known mutations.
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and 22,885 neutral variants from ClinVar (4,308) and our local database (18,577). The best performing methods 
in this test were MPPS and MutationTaster. The percentage of correct predictions of MutationTaster is 96.56% for 
pathogenic variants and 86.84% for neutral variants respectively. MPPS was able to correctly predict 97.12% of 
credibly pathogenic mutations and 95.21% of the credibly benign variants. There was a noticeable problem with 
several of the deleteriousness prediction programs: the lack of output because of the method’ inability to predict 
pathogenicity for a specific variant31. So we introduced the concept of Prediction Coverage. Prediction Coverage 
is defined by dividing the number of predicted variants (correctly or in correctly) by the total number of variants 
evaluated. Prediction Coverage was used to evaluate if all the variants can be predicted with a precise result or 
not. As shown in Fig. 1, 100% of variants (48,105/48,105) were successfully covered by MPPS, which is even better 
than MutationTaster (97.73%). MPPS could also make a great contribution to the automating result interpretation 
and reporting system in the next step.
Automating result interpretation and reporting system. In this study, we developed a web-based 
framework named AADSM (Automating Annotation and Diagnosis System for Mendelian disease) for automat-
ing analysis of clinical NGS data (Fig. 2). Clinical scientists can use this website to get information directly for 
diagnostics of Mendelian diseases by uploading the VCF (variant call format) file and the patients’ phenotypes.
Before analysis, we build our own gene-phenotype database and a scoring system. We use the gene-phenotype 
database and the scoring system to allow clinical researchers to carry out analysis of variant data, and help them to 
make a precise diagnosis for the patients. AADSM accepts variants input in the VCF formats. Patients’ phenotype 
also need to be upload before analysis (Fig. 2). The server performs a three step analysis process automatically, 
which mainly includes variant filtering and phenotype analysis, scoring, sorting and reporting. In the first step, 
all the variants will be filtered and annotated with our databases. At the same time, a gene list will be generated 
according to the clinical phenotype uploaded. In the second step, all the filtered mutations will be sorted using 
the scoring system we developed. The scoring system relies on the following rules: mutation frequency, mutation 
type, the consequence of a variant, and predicted categories from HGMD to determine the rank of a variant. In 
order to find the most related disease, the gene list generated in the first step will also be sorted using the scoring 
system. In the last step, a report will be automatically reported based on gene-disease relationship. The diseases 
and mutations with the highest score will be automated reported. Analysis results were presented in HTML pages, 
which contain all the details of annotation and the diagnosed diseases. These results can help clinical scientists to 
efficiently integrate variant related information and form a whole picture of their data more quickly.
To demonstrate the method’s diagnostic efficacy, we tested 56 patients in this study. A total of 85 disease caus-
ing mutations in the 56 patients were validated by methods other than NGS technology and identified previously 
by experienced researchers in this field. All the 56 patients were then diagnosed to be with specific Mendelian 
diseases according to the mutations identified. We also performed AADSM for automating analysis of clinical 
NGS data of the 56 patients. All the 85 disease causing mutations identified by experienced researchers were 
also detected by AADSM. In the 56 patients, the clearly diagnosed diseases in 32 patients (57.14%) ranked first 
in all the reported diseases, the clearly diagnosed diseases in 45 (80.36%) patients ranked top ten, and the clearly 
diagnosed diseases in 55 (98.21%) patients ranked top one hundred (Supplementary Material). These results can 
greatly assist and enhance Mendelian diseases diagnosis for clinical scientists and help to make a precise diagnosis 
for the patients.
Identification and characterization of disease causing mutations. In this study, a total of 219 disease 
causing mutations were detected, including 129 missense, 26 nonsense, 33 Indel, 15 splicing and 16 CNV. 43.84% 
(96/219) of disease causing mutations has never been reported before (Supplementary Material). Of all the 303 
random patients, 50.17% (152/303) were found to have deleterious mutations and have molecular confirmation 
Figure 1. Accuracy and coverage of 17 prediction programs.
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of the clinical diagnosis (Fig. 3). The 152 patients belonged to 9 clinical classifications. It was also observed that 
Urinary system disease (20.46% of all the 152 positive patients), Eye disease (14.19%), and Neuromuscular dis-
ease (8.91%) were the most frequently detected clinical category in our cohort (Fig. 3). Cataract (22 patients), 
Alport Syndrome (16 patients), and Retinitis pigmentosa (10 patients) were found to contain the most patients 
(Supplementary Material). The results strongly suggested that targeted NGS technique is an informative and 
effective approach to make a precise diagnosis for patients with Mendelian diseases, and has great potential to be 
used in real clinical practice.
A total of 85 (38.81%) of identified pathogenic mutations were tested and confirmed by Sanger sequencing 
(Supplementary Material). Co-segregation analysis was also performed among some patients’ family members. 
The validation further confirmed the clinical diagnosis of the patients.
Figure 2. Automating annotation and diagnosis system for Mendelian disease (AADSM). AADSM is a web-
based automating annotation and diagnosis system, which can assist and enhance diagnostics of Mendelian 
diseases.
Figure 3. Positive patients found to have deleterious mutations and have molecular confirmation of the clinical 
diagnosis.
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Discussion
Accurate and timely detection of disease causing mutations in patients with Mendelian diseases plays a pivotal 
role in the era of personalized medicine. Because the involved genes number is large, traditional methods can-
not be used to make a precise genetic diagnosis at a time5. With the rapid development of NGS, comprehensive 
characterization of genetic diseases using NGS technology has become an option for researchers and clini-
cians3,4,6,11–14,32,33. It has been proved that NGS based technology is a powerful tool for the detection of pathogenic 
mutations, especially in patients with Mendelian diseases.
In this study, we designed a new chip (array based) containing 4,689 genes related to Mendelian diseases, and 
performed targeted region enrichment and NGS for comprehensive mutation detection in 303 clinical cases. We 
reported disease causing mutations in 152 patients out of 303 random patients using targeted NGS. A total of 
219 disease causing mutations (including 96 novel mutations) were identified. Some researchers reported that 
~25% random patients were found to have deleterious mutations8. Based on our experience, the detection rate is 
highly dependent on the experience of the clinical scientist. In this study, all the potential patients were collected 
by experienced clinical scientists. Comparing to the results of previously publications, we included more genes 
related to Mendelian diseases, the diagnostic yield was also improved1,3–5,8.
To test the accuracy of this method, we compared the SNPs of a YH cell line sample detected using targeted 
NGS technology with the genotyping results detected using SNP Array. In the selected loci, 4,407 out of 4,416 
genotypes detected by targeted NGS in sample C1 were accordant to the results detected by SNP Array, which 
means there are 9 genotypes inconsistent using targeted NGS and SNP Array. We did NOT validate these incon-
sistent genotypes in the present study because in our previous study1, we also found 5 inconsistent genotypes 
when accessing the accuracy of targeted NGS technology. It turns out that all the genotypes of inconsistent loci 
detected by targeted NGS were consistent with that of Sanger sequencing1, which suggested that our method 
could provide high accuracy.
As is known, the most common form of genetic variation is single nucleotide polymorphisms (SNPs) in 
human. With the development of NGS, the number of detected human genome SNPs grow rapidly. However, 
it is laborious and time-consuming to attain experimental knowledge about the possible disease association of 
the variants. Several methods have been developed for deleteriousness prediction of detected SNPs. However, 
the prediction capabilities of certain programs varied a lot. The correct prediction of the nonsynonymous SNVs 
pathogenicity of individual program may result in very poor performance. Here we developed a new method 
named MPPS for pathogenicity prediction of nonsynonymous SNVs. As is known, several prediction programs 
are unable to predict pathogenicity for specific sets of variants29. Figure 1 showed that the percentage of correct 
predictions of MPPS was higher than other methods for both pathogenic variants and neutral variants. In the first 
step of MPPS analysis, we found that a parameter of 3 (3 prediction methods with the most correct predictions for 
‘damaging’ SNVs and 3 prediction methods with the most correct predictions for ‘benign’ SNVs) could provide 
the best performance for pathogenicity prediction. When evaluating the performance of MPPS, we found that a 
parameter of less than 3 would reduce the accuracy of MPPS because one or two programs would dominate in the 
analysis process. We also found that a parameter of more than 3 would reduce the accuracy of MPPS because the 
accuracy will be reduced by some poor-performance programs. That’s the main reason we selected 3 prediction 
methods for both ‘damaging’ SNVs and ‘benign’ SNVs.
After obtaining the VCF files of the patients, the variants must be annotated and interpreted. This process is 
tedious and time-consuming, and require highly specific expertise in the domain of the analysis, not to mention 
the probability of the introduction of human errors. We developed a web-based framework named AADSM for 
automating analysis of clinical NGS data. AADSM could provide a complete solution in assisting and enhancing 
Mendelian diseases diagnosis. We could analyze ~20 patients at a time using AADSM. The overall running time 
of AADSM is related to the variant number of the VCF file. Typically, the whole process took 8 to 20 minutes for 
20 samples. The data of the patients are stored and managed over AADSM in a secure manner. Before the submis-
sion of this manuscript, AADSM (http://jiyinsou.bgidx.cn/geneM/geneDiagnoseUpload.html) is still under test, 
and will be online in the near future.
In conclusion, we have developed a novel single test based on targeted NGS approaches for molecular diag-
nosis of various Mendelian disorders. In this method, we developed a new deleteriousness prediction method 
for nonsynonymous SNVs, and an automating annotation and diagnosis system for Mendelian diseases. A total 
of 303 patients were tested using this targeted NGS approaches. And we identified 219 disease causing muta-
tions. The results proved that this method is an informative and effective approach to make a precise diagnosis 
for patients with Mendelian diseases, and can greatly improve the implementation of targeted NGS in clinical 
practice.
Methods
Study participants. In the current study, a total of 303 patients were enrolled between April 2015 and June 
2017 in Tongji Hospital, Fuyang People’s Hospital and Renmin Hospital of Wuhan University. Clinical informa-
tion of the patients was also summarized by experienced doctor. To evaluate the accuracy and stability of this 
technology, 3 samples derived from YH cell line (C1, C2 and C3) and 9 probands (Table 1) with known disease 
causing mutations were also collected. Written informed consent was obtained from all the participants or their 
parents before sample collection. This study was approved by the ethics committee of BGI (BGI-IRB15083).
Capture design, library preparation and sequencing. This study was approved by the Institutional 
Review Board of BGI and was carried out in accordance with the approved guidelines. We designed a new custom 
human array spanning 10,258,198 bp (~10 M, Roche NimbleGen). The array targets exons and 10 bp flanking 
intronic sequences of a total of 4,689 Mendelian diseases related genes, which were collected based on 6 well 
known databases (OMIM (www.omim.org), GeneReviews (www.ncbi.nlm.nih.gov/books/NBK1116), Orphanet 
www.nature.com/scientificreports/
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(www.orpha.net), GENE Tests (www.genetests.org), CTGT (ctgt.net) and Genetics Home Reference (ghr.nlm.
nih.gov)). A total of 4,413 Mendelian diseases can be diagnosed using this array. The 4,413 Mendelian diseases 
can be classified into 19 clinical categories (Fig. 4), including 870 Neuromuscular system disease, 547 Metabolic 
disease, 522 Growth and development abnormal, 344 Eye disease, 299 Bone disease, 241 Mental retardation and 
related syndromes, 238 Skin disease, 224 Circulatory system diseases, 203 Immune and infectious diseases, 173 
Deafness and related syndromes, 169 Blood disease, 146 Endocrine system diseases, 111 Urinary system dis-
ease, 73 Reproductive system diseases, 72 Digestive system diseases, 51 Psychiatric and behavioral abnormal, 48 
Cancer and Tumor Syndrome, 47 Respiratory system diseases, and 35 Oral disease.
Using the QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany), genomic DNA of all the participants was 
isolated from the samples’ peripheral blood according to the manufacturer’s standard procedure. Library prepa-
ration was conducted at BGI following the guide of the standard protocol1. Briefly, 1 µg of genomic DNA was ran-
domly fragmented to ~250 bp (Covaris S2). Next, end repair and A-tailing were performed. Then, adapters were 
ligated to both ends of the fragments. After purification, the adaptor-ligated DNA were subsequently amplified, 
purified, pooled, and hybridized to our ~10 M human array for enrichment. After library quality control, NGS 
libraries were then sequenced on HiSeq2500 or HiSeq4000 (Illumina) to generate paired-end reads.
Workflow of targeted NGS approaches. In this study, we developed a new bioinformatics analysis 
pipeline, including data filteration, sequence alignment, variants calling, annotation and automating reporting 
(Fig. 5).
First, raw sequencing reads (FASTQ files) were evaluated using SOAPnuke to generate “clean reads” for 
further analysis (removing low quality bases, adapters and other technical sequences). After reads filtering, 
the 100 bp clean reads were then aligned to human reference genome (hg19) with BWA and generated sorted 
BAM files using Picard. To improve read mapping, we then used GATK and Picard to perform local realignment 
and removal of PCR duplicates. Next, we used GAKT and in-house scripts to detect sequence variants (SNVs, 
Indels, CNVs, and microdeletions/microduplications) as reported before1. Variant annotation was performed 
using ANNOVAR34 with some modifications. In the annotation step, we downloaded 5 well known databases to 
facilitate annotation, including HGMD (www.hgmd.org), dbSNP (www.ncbi.nlm.nih.gov/SNP), 1000 Genome 
Figure 4. Flow diagram of bioinformatics analysis.
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(www.1000genomes.org), HapMap (www.hapmap.ncbi.nlm.nih.gov), dbNSFP (www.varianttools.sourceforge.
net/Annotation/DbNSFP) and a local database of our own11.
For SNVs detection, we developed a new pathogenicity prediction method MPPS (Mutation Pathogenicity 
Prediction Software) in this study. MPPS combined a total of 17 current deleteriousness-scoring methods and 
mainly took 3 steps to predict the pathogenicity of nonsynonymous SNVs. In the first step, choose the best 6 
prediction methods (3 prediction methods with the most correct predictions for ‘damaging’ SNVs and 3 predic-
tion methods with the most correct predictions for ‘benign’ SNVs) according to the position of a variant. When 
evaluating the performance of 17 deleteriousness prediction methods, we found that the prediction capabilities 
of certain programs varied a lot in human genome. For example, the percentage of correct predictions rate for 
‘benign’ SNVs of GERP++ is high in some region, but low in other region of the human genome. So we randomly 
selected subsets of SNPs in human genome to obtain the percentage of correct predictions of the 17 pathogenicity 
prediction methods. Then we compared the results obtained for the same region to choose the best 6 prediction 
methods. In the second step, calculate the prediction score of the variant according to the weight of the best pre-
diction methods (3 methods for ‘damaging’ prediction and 3 methods for ‘benign’ prediction). In this step, we 
assigned the variant a score of 10 when it is classified as ‘damaging’, a score of 5 when it is classified as ‘possibly 
damaging’, a score of 0 when it could not be classified, a score of −5 when it is classified as ‘possibly benign’, and a 
score of −10 when it is classified as ‘benign’ by a prediction method. The weight of a prediction method is defined 
as the percentage of correct predictions in the region. The prediction score of the variant from MPPS is the sum 
of the scores provided by individual tools according to the weight of the best prediction methods. In the last step, 
evaluate the pathogenicity of the variant. First, examine whether the variant is located in conserved positions 
using GERP++ and phyloP100way. If the variant is located in conserved positions, the prediction score of the 
variant from MPPS will be added one to the original quantity. A final score of −10 (benign) to 10 (damaging) 
will be generated for the best 3 ‘damaging’ SNV prediction methods and the best 3 ‘benign’ SNV prediction 
methods respectively. If the results from the best 3 ‘damaging’ SNV prediction methods and the best 3 ‘benign’ 
SNV prediction methods are the same, the pathogenicity of the variant will be reported, if not, this procedure 
will be performed again by choosing the second best prediction methods until the results from the 3 ‘damaging’ 
SNV prediction methods and the 3 ‘benign’ SNV prediction methods are the same. This will be repeated until the 
results are the same, if not, the variant will be reported mis-classified.
We also developed an automating diagnosis and reporting system (AADSM, Automating Annotation and 
Diagnosis System for Mendelian disease) for clinical scientists to help themselves in assisting and enhancing 
diagnostics of Mendelian diseases. Finally, clinical reports of the patients will be generated.
Validation. Clinical disease causing mutations identified using the HiSeq platform in the patients were con-
firmed by methods other than targeted NGS. If a pathogenic mutation was detected, segregation analysis was 
also performed for confirmation when the samples were available. For the validation and co-segregation analysis 
among the proband’s family members, we performed Sanger sequencing. We amplified regions of interest using 
polymerase chain reaction for sequencing (ABI 3730).
Data Availability. The datasets generated during and/or analyzed during the current study are not publicly 
available, but are available from the corresponding author on reasonable request.
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